Boulder, Colorado, U.S., September 22, 2026
Edgewise Therapeutics, Inc. has unveiled new preclinical pharmacology findings describing the differentiated mechanism of action (MoA) of its investigational cardiac sarcomere modulator EDG-7500, an oral therapy being developed for patients with symptomatic hypertrophic cardiomyopathy (HCM). The company reported that EDG-7500 targets the regulatory light chain (RLC) of the cardiac sarcomere and has demonstrated a profile designed to improve cardiac relaxation while preserving systolic function and cardiac reserve. Edgewise said the findings provide additional support for the development of EDG-7500 in both obstructive and nonobstructive HCM.
EDG-7500 Targets Cardiac Relaxation
According to Edgewise, EDG-7500 represents a first-in-class cardiac sarcomere modulator designed to influence the mechanics of the cardiac cycle without compromising overall systolic performance. The company has focused on the RLC as a therapeutic target because impaired relaxation is a central feature of symptomatic HCM. In preclinical models, EDG-7500 demonstrated positive lusitropic properties, meaning it improved the ability of the heart muscle to relax, while avoiding significant systolic liabilities. Edgewise reported that its research team screened more than 7,000 pharmacologically diverse RLC candidates before selecting molecules with the desired activity profile. The company believes the resulting diastolic-biased mechanism could address an important component of HCM pathology.
Clinical Development Supports Further Evaluation
The newly disclosed preclinical findings are also being considered alongside early clinical observations in patients with symptomatic HCM, which Edgewise said have been consistent with the preclinical pharmacologic profile. EDG-7500 has already been evaluated in the Phase 2 CIRRUS-HCM trial, a 12-week study involving patients with HCM. The company reported that the treatment was generally safe and well tolerated, with no clinically significant changes in left ventricular ejection fraction. These observations are relevant because maintaining systolic performance is an important consideration when developing therapies that modify cardiac contraction and relaxation. Edgewise is evaluating EDG-7500 in both obstructive and nonobstructive HCM, broadening its potential development scope across the disease spectrum.
Phase 3 Development Planned for EDG-7500
The latest announcement comes as Edgewise prepares to advance EDG-7500 into later-stage clinical development. The company expects to initiate a Phase 3 trial in the fourth quarter of 2026, subject to the applicable development and regulatory processes. HCM is a genetic cardiac disorder characterized by abnormal thickening of the heart muscle, which can interfere with normal relaxation and filling of the heart. Patients may experience shortness of breath, chest pain, fatigue, dizziness, irregular heart rhythms, and fainting, while the disease can also be associated with heart failure and other serious cardiovascular complications. Edgewise is therefore pursuing EDG-7500 as a potential therapeutic approach aimed specifically at restoring balance within the cardiac cycle. The company describes its broader strategy as developing therapies that fine-tune cardiac muscle function for serious cardiovascular diseases with significant unmet medical needs. The EDG-7500 program represents a central part of this strategy following Edgewise’s shift toward an exclusive focus on cardiovascular diseases. If subsequent clinical studies confirm the findings observed to date, the program could provide additional evidence for targeting cardiac sarcomere function and diastolic dysfunction in HCM. However, EDG-7500 remains an investigational therapy, and preclinical and early clinical findings do not establish its safety or efficacy for marketing purposes.
Source: Edgewise Therapeutics press release



